World Journal of Endocrine Surgery

Register      Login

VOLUME 2 , ISSUE 2 ( May-August, 2010 ) > List of Articles

REVIEW ARTICLE

Molecular Basis of Primary Hyperparathyroidism

Peyman Björklund, Lee F Starker, Annabelle L Fonseca, Tobias Carling

Citation Information : Björklund P, Starker LF, Fonseca AL, Carling T. Molecular Basis of Primary Hyperparathyroidism. World J Endoc Surg 2010; 2 (2):63-70.

DOI: 10.5005/jp-journals-10002-1024

Published Online: 01-08-2010

Copyright Statement:  Copyright © 2010; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

During the past decade and a half, studies of genetic predisposition, parathyroid tumorigenesis, and molecular genetics of familial hyperparathyroid disorders have started to unveil the molecular basis of pHPT. Primary HPT is found in several distinct disorders with autosomal dominant inheritance such as in multiple endocrine neoplasia type 1 (MEN1), MEN2A, the HPT-jaw tumor syndrome (HPT-JT), familial isolated hyperparathyroidism (FIHPT), autosomal dominant mild hyperparathyroidism (ADMH), and neonatal severe HPT (NSHPT).


PDF Share
  1. Populationbased health screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287-94.
  2. Familial Parathyroid Tumors: Diagnosis and Management. World J Surg 2009.
  3. Hyperparathyroidism in hereditary syndromes: Special expressions and special managements. J Bone Miner Res 2002;Suppl 2:N37-43.
  4. Vitamin D receptor genotypes in primary hyperparathyroidism. Nat Med 1995;1:1309-11.
  5. Vitamin D receptor alleles b, a, and T: Risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1. Biochem Biophys Res Commun 1997;231:329-32.
  6. Vitamin D receptor (VDR) and parathyroid hormone mRNA levels correspond to polymorphic VDR alleles in human parathyroid tumors. J Clin Endocrinol Metab 1998;83:2255-59.
  7. Molecular pathology of parathyroid tumors. Trends Endocrinol Metab 2001;12:53-58.
  8. Genomic medicine— an updated primer. N Engl J Med 2010;362:2001-11.
  9. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 1988;318:658-62.
  10. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2047-53.
  11. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994;78:1320-24.
  12. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in parathyroid adenoma. J Clin Invest 1989;83:2034-40.
  13. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-15.
  14. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005;19:2603-09.
  15. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001;107:1093-102.
  16. Chromosome 11 genomic changes in parathyroid adenoma and hyperplasia: Array CGH, FISH, and tissue microarrays. Genes Chromosomes Cancer 2008;47:639-48.
  17. Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study. J Clin Endocrinol Metab 1996;81:1736-39.
  18. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-27.
  19. Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer 2008;7:53.
  20. Activated beta-catenin in the novel human parathyroid tumor cell line sHPT-1. Biochem Biophys Res Commun 2007;352:532-36.
  21. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab 2007;92:338-44.
  22. Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. Endocr Relat Cancer 2010;17:1-6.
  23. Absence of stabilizing mutations of beta-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. J Clin Endocrinol Metab 2007;92:1564-66.
  24. An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling. PLoS Med 2007;4:e328.
  25. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 1998;83:1766-70.
  26. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2960-63.
  27. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998;83:2627-30.
  28. Somatic mutations of the MEN1 gene in parathyroid tumours. Nature Genet 1997;16:375-78.
  29. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994;330:757-61.
  30. Intragenic allelic loss and promoter hypermethylation of the RIZ1 tumor suppressor gene in parathyroid tumors and pheochromocytomas. Surgery 2003134932-39. discussion 9-40.
  31. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. J Clin Endocr Metab 1996;81:3663-67.
  32. Parathyroid tumor suppressor on 1p: Analysis of the p18 cyclindependent kinase inhibitor gene as a candidate. J Bone Miner Res 1997;12:1330-34.
  33. Parathyroid hyperplasia, adenomas, and carcinomas: Differential expression of p27Kip1 protein. Am J Surg Pathol 1999;23:288-95.
  34. Germline mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006;103:15558-63.
  35. Germline CDKN1B/ p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321-25.
  36. Mutational analysis of the extracellular Ca (2+)-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 1995;80:3107-10.
  37. Expression and sequence analysis of rad51: A candidate tumor suppressor gene on chromosome 15q in a region frequently deleted in parathyroid tumors. Clin Endo 1999;51:403-08.
  38. Analysis of the RAD54 gene on chromosome 1p as a potential tumor-suppressor gene in parathyroid adenomas. Int J Cancer 1999;83:80-82.
  39. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin Dinduced apoptosis. J Cell Biol 2008;182:459-65.
  40. Alpha-Klotho as a regulator of calcium homeostasis. Science 2007;316:1615-18.
  41. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007;317:803-06.
  42. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-74.
  43. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-31.
  44. Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 2008;93:4152-57.
  45. Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am J Pathol 2002;161:1299-306.
  46. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 2010.
  47. Allelic loss of the retinoblastoma tumor suppressor gene: A marker for aggressive parathyroid tumors? J Clin Endocr Metab 1996;81:3194-96.
  48. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endo 1996;45:195-200.
  49. Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003;349:1722-29.
  50. Gene expression of parathyroid tumors: Molecular subclassification and identification of the potential malignant phenotype. Cancer Res 2004;64:7405-11.
  51. Multiple endocrine neoplasia type 1: Clinical features and screening. Endocrinol Metab Clin N Am 1994;23:1-18.
  52. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-07.
  53. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998;95:1630-34.
  54. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999;96:143-52.
  55. Cell cycle regulation of menin expression. Cancer Res 1999;59:5097-101.
  56. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001;20:4917-25.
  57. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci USA 2001;98:3837-42.
  58. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res 2007;67:7275-83.
  59. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005;123:207-18.
  60. Mechanisms of disease: Multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat Clin Pract Endocrinol Metab 2006;2:562-70.
  61. Genetic basis of endocrine disease: Multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995;80:1989-95.
  62. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996;27:789-93.
  63. Hereditary hyperparathyroidism- jaw tumor syndrome: The endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995;56:944-50.
  64. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism- jaw tumor syndrome. Nat Genet 2002;32:676-80.
  65. Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol Cell Biol 2008;28:2930-40.
  66. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci USA 2008;105:17420-25.
  67. Familial hyperparathyroidism without multiple endocrine neoplasia. World J Surg 1997;1:22-28.
  68. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet 1998;63:1544-49.
  69. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab 2000;85:165-67.
  70. The calcium-sensing receptor: A window into the physiology and pathophysiology of mineral ion metabolism. Endocrine Rev 1996;17:289-307.
  71. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993;75:1297-303.
  72. Mutations in the calcium-sensing receptor and their clinical implications. Horm Res 1997;48:199-208.
  73. Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: Multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene. Am J Med Genet 1997;71:202-10.
  74. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 2000;85:2042-47.
  75. Calcium-sensing receptor (CASR) mutations in hypercalcemic states: Studies from a single endocrine clinic over three years. J Clin Endocrinol Metab 2010;95:1819-29.
  76. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995;11:389-94.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.